JMP Securities Sticks to Its Buy Rating for Protagonist Therapeutics (PTGX)
JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Protagonist Therapeutics (PTGX – Research Report) today and set a price ...
JMP Securities Sticks to Their Buy Rating for Cytokinetics (CYTK)
JMP Securities analyst Jason Butler maintained a Buy rating on Cytokinetics (CYTK – Research Report) today and set a price target of $78.00.
JMP Securities Raises Axon Enterprise, Inc. (AXON) Price Target to $725 on AI & Defense Demand
We recently compiled a list of the 8 AI Stocks on Investors’ Radar. In this article, we are going to take a look at where ...
Xometry appoints new CTO as Leibel departs
Mr. Leibel's departure, as stated in the company's SEC filing, is not due to any disagreements or disputes with the company's operations or practices. He will continue to serve as an employee until ...
JMP maintains Apollo stock Market Perform rating
JMP Securities maintained its Market Perform rating on Apollo Global Management (NYSE:APO) shares without setting a new price ...
Covers3d
Super Bowl Betting May Near $2B After ‘Customer Friendly’ NFL Season: Covers
The killing U.S. bettors made this NFL season could nudge legal sports betting on this year’s Super Bowl toward $2 billion in regulated action.
Uber Technologies Inc. (UBER): This AI Stock Is On Analysts’ Radars Right Now
Despite DeepSeek and Qwen 2.5 disrupting the global tech sector, investors welcomed the impressive Q4 AI revenues from leading US tech firms like International Business Machines Corp. (NYSE:IBM).
Why Pharvaris (PHVS) Is Advancing Today
Pharvaris (PHVS) is climbing 3% after investment bank JMP Securities raised its price target on the shares to $55, based on ...